MONTANARO, NICOLA
 Distribuzione geografica
Continente #
NA - Nord America 4.573
AS - Asia 4.088
EU - Europa 3.458
AF - Africa 211
SA - Sud America 199
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.541
Nazione #
US - Stati Uniti d'America 4.516
SG - Singapore 1.101
VN - Vietnam 1.074
CN - Cina 1.012
IT - Italia 933
GB - Regno Unito 767
DE - Germania 423
SE - Svezia 295
HK - Hong Kong 270
UA - Ucraina 261
FR - Francia 208
IN - India 177
RU - Federazione Russa 171
BR - Brasile 145
IE - Irlanda 106
JP - Giappone 105
KR - Corea 94
BD - Bangladesh 77
NL - Olanda 67
CI - Costa d'Avorio 64
ZA - Sudafrica 62
FI - Finlandia 48
EE - Estonia 37
CA - Canada 34
BE - Belgio 33
JO - Giordania 31
TG - Togo 31
PH - Filippine 28
AR - Argentina 25
GR - Grecia 20
AT - Austria 18
SC - Seychelles 18
TR - Turchia 16
ID - Indonesia 15
MX - Messico 15
NG - Nigeria 15
IR - Iran 14
CH - Svizzera 13
PK - Pakistan 12
AU - Australia 11
IQ - Iraq 11
PL - Polonia 10
TH - Thailandia 10
TW - Taiwan 10
HR - Croazia 9
CO - Colombia 8
BG - Bulgaria 7
EC - Ecuador 7
UZ - Uzbekistan 7
LT - Lituania 6
AL - Albania 5
CL - Cile 5
ES - Italia 5
MY - Malesia 5
PY - Paraguay 5
RO - Romania 5
EG - Egitto 4
KE - Kenya 4
TN - Tunisia 4
CR - Costa Rica 3
CZ - Repubblica Ceca 3
LB - Libano 3
MA - Marocco 3
VE - Venezuela 3
AZ - Azerbaigian 2
DZ - Algeria 2
KZ - Kazakistan 2
NP - Nepal 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BT - Bhutan 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
HN - Honduras 1
JM - Giamaica 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MU - Mauritius 1
NO - Norvegia 1
OM - Oman 1
PS - Palestinian Territory 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.541
Città #
Singapore 743
Southend 656
Ashburn 374
Santa Clara 365
Chandler 339
San Jose 326
Fairfield 293
Hong Kong 262
Dong Ket 239
Hefei 207
Ho Chi Minh City 207
Jacksonville 199
Princeton 183
Wilmington 170
Hanoi 158
Woodbridge 137
Ann Arbor 135
Houston 134
Seattle 132
Dallas 106
Dublin 106
Beijing 103
Tokyo 95
Cambridge 92
Los Angeles 91
Boardman 89
Lauterbourg 86
Seoul 84
Council Bluffs 72
Padova 69
Westminster 68
Abidjan 64
Bologna 63
Nanjing 62
Rome 58
Milan 49
New York 47
Mülheim 45
Buffalo 43
Helsinki 42
Berlin 39
Bremen 39
Medford 37
Saint Petersburg 35
Shenyang 34
Amman 31
Lomé 31
Haiphong 30
Brussels 29
Da Nang 28
San Diego 26
San Venanzo 26
Hebei 25
Florence 24
Nanchang 23
Jinan 22
Munich 22
Shanghai 22
Frankfurt am Main 21
Changsha 19
Guangzhou 19
Jiaxing 19
Redondo Beach 19
The Dalles 19
Palermo 18
Mahé 17
Phoenix 16
São Paulo 16
Zhengzhou 15
Bengaluru 14
Dearborn 14
London 14
Olalla 14
Orem 14
Abeokuta 13
Atlanta 13
Shenzhen 13
Tianjin 13
Wuhan 13
Biên Hòa 12
San Francisco 11
Verona 11
Brooklyn 10
Chicago 10
Fuzhou 10
Ningbo 10
Norwalk 10
Nuremberg 10
Bến Tre 9
Chennai 9
Falkenstein 9
Falls Church 9
Hangzhou 9
Kunming 9
Montreal 9
Pescara 9
Xi'an 9
Bühl 8
Ferrero 8
Haikou 8
Totale 7.848
Nome #
Leucoencefalopatia Multifocale Progressiva: complicanza dell'immunosoppressione o reazione avversa da farmaci? 605
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage 313
Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions 285
Le basi della farmacologia 262
A 3 year survey on the use of antibacterial agents in five Italian hospitals. 228
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. 215
Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy 215
Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement 214
Ticlopidine Safety Profile: A Case/Non-Case Study on the Basis of the Spontaneous ADRs Reporting in Italy 210
Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature 198
Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). 195
An approach to evaluate appropriateness in the antibacterial therapy in Italian hospitals. 190
Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. 189
An update on the first decade of the European centralized procedure: how many innovative drugs? 188
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. 188
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database 187
Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study 185
Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database 179
Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug’s safety profile. 175
Changes in prevalence and pattern of drug use in a ten years period in Italy. 8th Congress of the European Association for Clinical Pharmacology and Therapeutics 174
Dronedarone-associated acute renal failure: evidence coming from the Italian spontaneous ADR reporting database 168
Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data 167
Hepatic adverse drug reactions: a case/non-case study in Italy 157
Possible occurrence of paraesthesia in patients taking norethisterone: an analysis on the WHO Global Individual Case Reports database (VigiBase). 157
Comparative Safety Profiles of Biosimilars vs. Originators Used in Rheumatology: A Pharmacovigilance Analysis of the EudraVigilance Database 156
Developing a Method To Identify Prescribing Profiles of Antihypertensive Drugs in General Practice. 156
Non-commercial trials on medicines submitted to the Ethics Committee of the University Hospital of Bologna (Italy) along 8 years of activity: time to update rules and recommendations 156
Pattern of triptan use and cardiovascular coprescription: a pharmacoepidemiological study in Italy 155
A 5 years surveillance of antibiotic use and microbiological resistance in an Italian university hospital. 155
Triptans and serious cardiovascular events: possible safety signals from the FDA Adverse Event Reporting System database 155
Antibiotic use in Italian hospitals 2002-2004. 153
Pattern of NSAID use in the Italian general population: a questionnaire-based survey. 152
Gastro-intestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy 151
Six-year activity on approval of compassionate use of medicines by the Ethics Committee of the University Hospital of Bologna (Italy): time to update rules and recommendations 151
The adherence to antihypertensive treatments: an Italian survey by using prescription databases. 150
Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy 149
Level of therapeutic innovation from the registration studies of the new drugs for the prophylaxis of migraine 147
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy 147
Progressive Multifocal Leukoencephalopathy: an effect of immunodeficiency or an adverse drug reaction? 146
Cardiovascular events in statin recipients: a 3-year record-linkage study on prescription and hospital discharge databases 143
Therapeutic innovation of the drugs approved by the EMEA-centralised procedure 142
Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. 142
La rimborsabilità di memantina - il trilemma di Münchausen 142
Safety profile of thiazolidinediones on the basis of the FDA-AERS database: cardiovascular and bone fracture risks for rosiglitazone and pioglitazone 142
Initial treatment of hypertension and adherence to therapy in general practice in Italy 142
Un commento alla lettera sulla definizione di farmaco innovativo 140
Analyses of natalizumab prescriptions and discontinuations in multiple sclerosis patients of an Italian region 139
Risk-management of natalizumab: a drug utilization study on duration of therapy and cause of discontinuation in Emilia-Romagna region 139
Human papilloma virus vaccination in males: A pharmacovigilance study on the Vaccine Adverse Event Reporting System 139
Progetto europeo di confronto dell'uso dei farmaci 136
Assessing the risk of Osteonecrosis of the Jaw (ONJ) due to bisphosphonates (BP) therapy in the secondary prevention of osteoporotic fractures 134
Antibiotic Use and Microbiological Surveillance: An Ecological Study in an Italian University Hospital. 134
Safety profile of paediatric COVID-19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System 132
Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database. 131
Progressive Multifocal Leukoencephalopathy (PML): only immunosuppressive complication or also drug adverse reaction? 130
Assessing the risk of Osteonecrosis of the Jaw (ONJ) due to Bisphosphonates (BP) therapy in the secondary prevention of osteoporotic fractures, 124
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice 124
Pattern of Triptan Use in a Sample of the Italian General Population 123
The Influence of Notoriety Bias on ADR Spontaneous Reporting Rate. 122
Farmaci EMEA ed innovazione terapeutica 122
The pharmacovigilance program on natalizumab in Italy: 2 years of experience 122
Natalizumab: a country-based surveillance program 121
Three years of experience: the Italian registry and safety data update 120
Prevenire gli errori in terapia. Strategie per i farmacisti 117
Removal of the EMA orphan designation upon request of the sponsor: cui prodest? 115
Progetto di monitoraggio della prescrizione di farmaci disease-modifying nella sclerosi multipla in Emilia-Romagna 113
Ticlopidine’s safety profile: a case/non case study on the basis of the spontaneous ADR reporting in Italy. 110
Monitoring the use of disease-modifying drugs in multiple sclerosis 110
The Italian Surveillance Program on Natalizumab 107
Hepatic adverse drug reactions: analysis of an italian spontaneous reporting database. 103
Prescrizione di Entacapone nella Regione Emilia-Romagna 99
Monitoring disease-modifying drugs in multiple sclerosis in Emilia Romagna 98
La medicina basata sulle prove - Istruzioni per l'uso. Prima edizione italiana 97
The Italian Natalizumab Registry: a 1-year follow-up 96
La medicina basata sulle prove. Dalle fonti di conoscenza alla realtà del singolo paziente. Seconda edizione 96
Pattern of use of NSAIDs in the Italian general population: a questionnaire-based study 95
Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database 89
Safety of Proton Pump Inhibitor in Paediatrics: A Study Based on EudraVigilance Data 83
Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis 82
On criteria to evaluate the therapeutic innovation of drugs 80
Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data 75
Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab 63
Overview of Orphan Medicines in European Union: An Analysis of Regulatory and Technical-Scientific Aspects 60
Use of benzodiazepines in the Italian general population: Prevalence, pattern of use and risk factors for use 48
Use of anti-asthmatic drugs in Italy: Analysis of prescriptions in general practice in the light of guidelines for asthma treatment 47
Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview 43
Adverse drug reactions related to the use of fluoroquinolone antimicrobials: An analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions 29
Totale 12.763
Categoria #
all - tutte 33.622
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.622


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021343 0 0 0 0 0 0 0 0 0 0 0 343
2021/20221.412 184 49 62 98 120 66 25 93 51 91 355 218
2022/20231.483 159 183 100 203 99 128 28 86 261 45 127 64
2023/2024498 46 69 37 60 42 43 32 42 22 39 50 16
2024/20251.731 69 230 143 86 440 132 87 52 30 55 81 326
2025/20264.281 240 370 408 340 502 202 548 176 717 335 249 194
Totale 12.763